2026-09-30 · 2026-09 / week-5
Conagra’s FY27 Guide Is Weak; the Pre-Report Short Still Fails 10/5
Conagra’s FY27 Guide Is Weak; the Pre-Report Short Still Fails 10/5
Summary: Conagra’s fiscal 2027 guide already calls for lower organic sales and margin, and the Sep. 30 before-open Q1 release is a near-term test. But at $14.005, CAG trades at about 9.66x management’s $1.45 adjusted-EPS midpoint, after falling roughly 13.1% since Sep. 1. A reference-only event map has a flat base and a +15.0% rebound stress; the expected gross short return is about -1.1% before costs. Reject / no trade.
Opportunity Ranking
This U.S.-only short screen compares Conagra’s pre-result volume and margin risk, Conduent’s scheduled investor day after weak Q2 results, CarMax’s freshly reported Q2 recovery, Jabil’s Sep. 30 fiscal-year results, and SPY as a broad-market baseline. CAG ranks first for information value, not as an executable short.
| Rank | Candidate | Direction | Mispricing | Evidence Freshness | Catalyst Window | Positioning | 10/5 Status | Tradeability | Main Rejection Risk |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Conagra Brands (CAG) | Short | FY27 guidance is for organic sales down 1%-3% and a lower adjusted operating margin, but $14.005 already equals about 9.66x the $1.45 adjusted-EPS midpoint; it is unclear that one more quarter supports another de-rating | FY26 issuer release, Sep. 24 dividend notice, Sep. 30 Q1 date, Sep. 29 12:55:02 p.m. EDT price reference | Q1 FY27 release before the market opens Sep. 30; live Q&A at 9:30 a.m. ET | Short interest, borrow/recall and current positioning not verified | Reject: 0% base decline, +15.0% observed-level rebound stress, 0:1 base reward/adverse ratio | NYSE common; regular-session reference only; locate, spread, depth and exit capacity not verified | The reset dividend, lower leverage and existing guide may already reflect the bad news; branded-food demand and volume share can stabilize |
| 2 | CarMax (KMX) | Short | Q2 revenue grew 19.5% and net income 73.3%, while retail and wholesale gross profit per unit fell; shares were +4.3% at $59.00 in the latest 12:55 p.m. ET feed snapshot | Sep. 29 issuer 8-K and Q2 release; finance-feed quote 12:55:11 p.m. ET | November 3 Strategic Update | Short interest and borrow/recall not checked | Reject: strong current operating evidence; no sourced 10% base decline or +5% adverse cap | NYSE common with substantial normal turnover; no live execution audit | CAF income rose partly from a lower loan-loss provision and a $16.6M loan-sale gain, but the large unit-volume rebound and 81% EPS growth are real counterevidence |
| 3 | Conduent (CNDT) | Short | Q2 continuing revenue fell 11.9% and adjusted EBITDA margin was 3.0%; however, two signed sales are expected to generate $234M gross and management’s Sep. 30 investor day may add material terms or an operating plan | Aug. 10 issuer Q2 release; Sep. 24 investor-day notice; Sep. 29 12:45 p.m. ET finance-feed reference | Sep. 30 investor day, 8:25 a.m.-12:30 p.m. ET | Current short interest, borrow and event positioning not verified | Reject: proceeds, cash/debt allocation and future plan make a supportable 10/5 map incomplete | Low-priced Nasdaq common; locate, spread, depth and exit capacity require separate verification | The sales are signed, not completed cash; an investor-day update could narrow the uncertainty in either direction |
| 4 | Jabil (JBL) | Short | Strong Q3 results and AI-infrastructure commentary precede Sep. 30 Q4 results and FY27 priorities; no current primary evidence yet shows deterioration in the end-market bridge | Jun. 17 issuer Q3 results; Sep. 9 Q4 date notice; Sep. 29 12:55 p.m. ET finance-feed reference | Sep. 30 before open; call at 8:30 a.m. ET | Positioning and borrow not reviewed | Reject pending report: no current-quarter downside or responsible 10/5 map | NYSE common; regular-session liquidity appears greater than small caps, but no current execution audit | Q3 revenue was $8.8B, core EPS $3.16, and management raised FY26 outlook while citing strong AI-infrastructure demand |
| 5 | SPDR S&P 500 ETF (SPY) | Short | The broad index was down about 0.3% at the latest feed snapshot, but no issuer-specific catalyst or one-week 10% downside case is identified | Sep. 29 12:54 p.m. ET finance-feed snapshot | Rates, oil and geopolitical developments remain two-sided | Index positioning not reviewed | Reject: no evidence-backed 10% base decline or +5% adverse bound | Highly liquid during regular hours; no order-book snapshot captured | Any easing in yields or energy risk can reverse a macro-driven move |
Selected opportunity: CAG for information value, not as an executable short.
Why this one now: The fiscal Q1 result is due before the Sep. 30 U.S. open, and the latest filed annual bridge shows lower organic sales, sharply weaker gross profit and free cash flow, a halved dividend, and leverage that management expects to rise modestly this year. Yet the stock is already near its 52-week low and the FY27 adjusted-EPS guide is visible to investors.
What should surprise the reader: CAG’s annual report-card weakness is real, but the price does not imply a high multiple: $14.005 is about 9.66x the midpoint of management’s $1.40-$1.50 FY27 adjusted-EPS range. The short needs another estimate reset, not merely another reminder of the July guide.
Why CAG Ranks First for Information Value
Conagra’s July 15 FY26 release reported organic sales down 0.4% for the year, gross margin down 194 basis points to 23.9%, adjusted gross profit down 9.4%, and free cash flow of $979M versus $1.3B the prior year. The full-year report included a 53rd week; reported sales declined 2.9%, with M&A also affecting the comparison. The organic measure removes foreign exchange, acquisitions/divestitures, and the extra week.
The FY27 outlook expects organic net sales down 1%-3%, adjusted operating margin of 10.0%-10.5%, and adjusted EPS of $1.40-$1.50. Its key assumptions include roughly $360M interest expense, $550M capex, more than 90% free-cash-flow conversion, and year-end net leverage around 4.0x. The prior FY26 close was $7.1B net debt and 3.83x leverage. These are company estimates, not an independent forecast.
The prior-year Q1 comparison was already weak: Conagra reported 0.6% lower organic sales, driven by 1.2% lower volume partly offset by 0.6% price/mix, and adjusted EPS of $0.39. The Sep. 30 Q1 report will test whether that pressure is continuing, stabilizing, or easing. The report release is scheduled before the open; the issuer has specified a live Q&A at 9:30 a.m. ET but has not published an exact release time.
Why This Can Move More Than 5% Soon
The Q1 release and management Q&A are dated within the next U.S. session. The stock has fallen from $16.11 on Sep. 1 to a $14.005 intraday reference on Sep. 29, a 13.1% decline. That move may already reflect the dividend reduction, impairment, and weaker FY27 guide. StockAnalysis lists a $12.53-$20.32 52-week range, so the price is near the low but not at a protected floor.
The Sep. 30 figures could move CAG by more than 5% in either direction, but that is a catalyst-risk observation, not evidence of a prospective short edge. The result may show further volume and margin deterioration, or it may confirm the guide and relieve concern that was already capitalized into a low adjusted-EPS multiple.
10/5 Asymmetry Gate
This is a reference-only price-path sensitivity through Oct. 2, 2026, not fair value or a calibrated forecast. The reference is $14.005 at Sep. 29, 12:55:02 p.m. EDT / 16:55:02 UTC. StockAnalysis’s separate S&P Global snapshot showed $14.09 at 12:28 p.m. EDT; the observations are 27 minutes apart, not simultaneous quotes. No current bid/ask, spread, depth, borrow, or exit-liquidity data is available.
The scenario levels use two observed price references: the $12.53 52-week low and the Sep. 1 close at $16.11. They are not floors, caps, or analyst price targets. The 25% / 50% / 25% weights are subjective. The base gets the largest weight because the FY27 guide is already public but Q1 actuals and a verified analyst surprise range are not; a roughly in-line release therefore has no sourced reason to force a second reset. The top and bottom weights split the risk that reported volumes and margins either deteriorate or stabilize after the dividend and guide reset.
| Scenario | Probability | Target / Level | Return from $14.005 | Horizon | Conditions | Evidence Quality |
|---|---|---|---|---|---|---|
| Top Case | 25% | $12.53 | 10.5% underlying decline | Through Oct. 2, 2026 | Q1 results show a further volume or margin break, FY27 guidance is cut, and the stock retests its observed 52-week low | Low; observed level, subjective path probability |
| Base Case | 50% | $14.005 | 0.0% underlying decline | Through Oct. 2, 2026 | Q1 is broadly consistent with the already-disclosed FY27 range; investors wait for more evidence on volumes, costs, and cash conversion | Low; reference hold, not a forecast |
| Bottom Case | 25% | $16.11 | 15.0% underlying rise | Through Oct. 2, 2026 | Q1 or the Q&A reassures on pricing, volume and cost savings; price revisits the observed Sep. 1 close; higher prices remain possible | Medium as an observed close; low as a forecast |
| Invalidation | n/a | Evidence trigger, not price stop | The next report confirms FY27 guide, improves organic volume/adjusted margin, and supports the stated cash-conversion path | Sep. 30 Q1 release and Q&A | Rebuild after the release; distinguish price/mix, volume, segment margins, working capital, FCF, capex, and net debt | Medium |
Probability-weighted expected value: $14.1625 per share, or -1.1% gross short return before borrow and execution costs: 1 - (0.25×12.53 + 0.50×14.005 + 0.25×16.11) / 14.005.
Current market level and timestamp: $14.005 at Sep. 29, 12:55:02 p.m. EDT / 16:55:02 UTC; regular session.
Primary instrument: CAG common stock on NYSE, research only.
10/5 favorable base move: 0.0% decline; the 10.5% top-case decline is not the highest-probability case.
10/5 credible adverse move: +15.0% retest of the Sep. 1 close; not a ceiling.
10/5 measurement basis: Reference-only; entry.price is null.
10/5 status: Reject.
Confidence: Low.
Sensitivity: using the Sep. 4 close of $15.48 rather than Sep. 1’s $16.11 as the upside stress still leaves a +10.5% adverse rise from the reference, while the base remains flat. Neither that narrower adverse case nor a 9x multiple on the $1.40 low end of FY27 adjusted-EPS guidance ($12.60, a 10.0% top-case decline) changes the zero-base-move failure. The multiple sensitivity is an analyst assumption, not a valuation claim.
What Should Surprise the Reader
The FY26 impairment does not equal an operating cash loss: the company reported a $4.00 full-year diluted loss per share primarily from non-cash goodwill and brand impairments, alongside $1.72 adjusted EPS. But the operating bridge also weakened independently of that accounting charge: adjusted gross profit fell 9.4%, adjusted gross margin fell 175 basis points, and free cash flow fell roughly 25% year over year. The correct short question is whether FY27 estimates need another reset, not whether the impairment makes GAAP EPS look ugly.
The cash and liability picture cuts both ways. Net debt fell to $7.1B and 3.83x net leverage at FY26 year-end, but FY27 guidance assumes approximately 4.0x leverage and $360M interest expense. Halving the dividend reduces the annualized payment to $0.70 per share; it also tells investors management is conserving capital while the operating recovery remains unproven.
The Setup
Conagra sells branded grocery, refrigerated and frozen, international, and foodservice products. The short-side thesis is that price increases and productivity may fail to offset volume declines, inflation, and operating leverage. Evidence in the last full year supports that risk. The contrary view is that the July reset deliberately lowered the bar: cost actions, category share gains in Q4, reduced debt, and a smaller dividend may make even flat volumes sufficient to meet guidance.
The issuer’s Q1 FY26 release reported organic sales down 0.6%, with volume down 1.2% and price/mix up 0.6%. That establishes a weak but not collapsing baseline. For Q1 FY27, I do not have sufficient reliable primary-source data to quantify the current quarter’s segment consensus, order trends, or expected earnings surprise accurately.
The Market Price
| Observation | Value | Timestamp | Source / limitation |
|---|---|---|---|
| Current intraday reference | $14.005 | Sep. 29, 12:55:02 p.m. EDT / 16:55:02 UTC | Finance-feed snapshot; no NBBO, spread or depth audit |
| Cross-check | $14.09 | Sep. 29, 12:28 p.m. EDT | StockAnalysis/S&P Global; 27-minute-earlier vendor snapshot |
| Previous regular close | $14.16 | Sep. 28, 4:00 p.m. EDT | StockAnalysis/S&P Global |
| Sep. 1 regular close | $16.11 | Sep. 1, 4:00 p.m. EDT | StockAnalysis/S&P Global; observed-level stress only |
| 52-week range | $12.53-$20.32 | Vendor page checked Sep. 29 | Context only; neither end is a floor or ceiling |
At $14.005, price divided by the midpoint of Conagra’s FY27 adjusted-EPS guidance ($1.45) is approximately 9.66x. This is a price-to-adjusted-guidance ratio, not enterprise value or GAAP earnings. StockAnalysis shows a Hold consensus and $14.41 average 12-month target from 17 analysts, but the aggregation is secondary and does not provide a verified Q1 EPS consensus. The figure is context, not proof of mispricing.
The Mispricing
Fact: Conagra’s FY27 outlook anticipates organic sales contraction, a lower adjusted operating-margin range, and adjusted EPS below FY26’s $1.72. Fact: FY26 free cash flow declined by about $321M, net debt remained $7.1B, and leverage was 3.83x. Inference: a short can work if Q1 sales volume and costs force another guidance reduction. Counter-inference: after a 13.1% decline from Sep. 1, 9.66x guided adjusted EPS and a reduced dividend may already price much of the deterioration.
I do not have a reliable primary-source Q1 consensus estimate or current market-implied EPS expectation. The Sep. 30 result can establish the operating boundary; the public evidence available before the report does not show that CAG is mispriced by the amount needed for a short.
The Positioning
Current short interest, days-to-cover, utilization, borrow fee, recall terms, options positioning, fund flows, and market-maker exposure were not verified. The share’s recent decline is price evidence, not proof of crowded positioning. The retrieved quote is a single feed observation, not an executable market.
The Catalyst
- Q1 FY27 release: Conagra says the press release and supplemental materials will be issued before the Sep. 30 market open. Test organic price/mix against volume by segment, adjusted gross margin, restructuring, working capital, and whether the $1.40-$1.50 EPS guide changes.
- Live Q&A: The company scheduled the investor Q&A for 9:30 a.m. ET on Sep. 30. Reconcile answers on inflation, volume elasticity, advertising, inventory, tariff/input costs, and cost savings against the filed release.
- Cash and leverage: Compare operating cash flow and capex with the company’s greater-than-90% FCF-conversion and approximately 4.0x year-end leverage assumptions. Guidance is not a completed cash result.
The cheapest falsification is the Sep. 30 Q1 release plus the live Q&A. If Conagra holds its guide and describes sequential volume stabilization without deterioration in cash conversion, the immediate short thesis weakens. If management cuts guidance, separate the size of the estimate change from the first-session price response before rebuilding a scenario map.
The Payoff
Strongest short argument: the company’s organic sales and gross margin have weakened, FY27 guide still implies contraction, and leverage is expected to increase from 3.83x to about 4.0x while interest expense remains approximately $360M.
Strongest counterparty case: CAG has already de-rated to roughly 9.7x adjusted EPS guidance and is near its 52-week low. The dividend reset preserves capital, net debt decreased during FY26, and Q4 share gains in several categories could persist. Q1 is a test of a lower guide, not an unannounced deterioration.
The short therefore depends on an additional reset rather than the published guide itself. No primary evidence available at this cutoff establishes that reset as the highest-probability outcome.
The Kill Shot
The load-bearing short assumption is that Q1 confirms further volume/price weakness severe enough to lower the FY27 earnings range. It fails if the report holds guidance, Q1’s prior-year comparison proves easier than feared, and the market values the dividend reset and debt reduction as sufficient stabilization.
The trade can lose even if the long-run operating thesis is right: a quarterly beat or one-off working-capital release can cause a sharp squeeze before earnings estimates catch down; higher food prices can hold dollar sales while volume weakness improves; and CAG has a high dividend yield that creates short carry. None of these paths is bounded by a stop.
What Could Go Wrong
The release may attribute reported-sales changes to foreign exchange or divestitures rather than underlying demand. Foodservice or refrigerated/frozen could offset weakness in grocery/snacks or international. A lower dividend may fund deleveraging more effectively than the market expects. Conversely, a guide cut could still fail to produce another 10% base decline if investors already expect it. The 52-week low is a historical price, not a downside floor; the Sep. 1 close is not an upside cap.
What Would Prove This Wrong
The immediate short case weakens if the Sep. 30 release keeps FY27 guidance, shows organic volume stabilization, and supports the adjusted-margin range with actual cash flow rather than inventory timing. It strengthens if volume declines worsen across segments, adjusted gross margin falls below the guided range, or management cuts the FY27 EPS outlook. Re-underwrite from a fresh regular-session quote after the release; do not use this reference-only map as an entry instruction.
Risk Audit
- Known versus missing: FY26 sales, margin, cash flow, net debt, leverage and FY27 guidance are issuer-reported. Q1 actuals, current positioning and market microstructure are unknown at publication.
- Earnings quality: Adjusted EPS excludes items affecting comparability. Do not treat it as GAAP net income or free cash flow.
- Valuation: 9.66x uses adjusted-EPS midpoint guidance; debt, leases and other senior claims are not in that price ratio.
- Gap and squeeze: The event is binary and the bottom case uses a prior close, not a limit. A favorable result can gap beyond $16.11.
- Execution: No current locate, borrow cost, recall, NBBO, spread, depth, venue quality, volume quality, or exit capacity is verified.
- Forecast calibration: No recent CAG short forecast exists in the active September log; horizons for current week’s other screens remain prospective and are not scored here.
Best Trade Strategy
No trade. Do not initiate a short before the Sep. 30 results. The most likely reference case is flat; the observed-level upside stress is +15.0%; gross expected short value is negative before costs; and there is no verified locate or liquidity audit. Reassess only after the full Q1 release, Q&A, fresh regular-session acceptance, current loan/borrow terms, and an updated 10/5 map. Common stock research only; no options, leverage, margin, market orders, price-floor language, or short without a verified locate.
Sources
| Source | Date / observation | Use |
|---|---|---|
| Conagra Q4 FY26 and FY26 issuer release | Jul. 15; FY ended May 31 | FY26 sales, organic volume/price mix, margin, impairment, cash flow, net debt, leverage, dividend reset, and FY27 guidance |
| Conagra Q1 FY27 release-date notice | Aug. 31; checked Sep. 29 | Confirms before-open release and 9:30 a.m. ET Q&A |
| Conagra Q1 FY26 issuer release | Oct. 1, 2025 | Prior-year Q1 organic volume and earnings comparison |
| Conagra Sep. 24 dividend notice | Sep. 24 | Confirms quarterly dividend remains $0.175 per share |
| CAG price history and CAG overview | Sep. 29, 12:28 p.m. EDT; finance-feed quote at 12:55:02 p.m. EDT | Current reference, previous close, day range, recent closes, 52-week range, and secondary analyst aggregate; feed quotes are not NBBO or order-book evidence |
| CarMax Q2 FY27 8-K and Exhibit 99.1 and Q1 FY27 issuer release | Sep. 29; Jun. 17 | Candidate comparison: Q2 growth, per-unit gross profit, CAF provision/gain-on-sale, share-repurchase plan, and earlier operating baseline; first link is a third-party rendering of the SEC filing and issuer exhibit |
| Conduent Q2 2026 issuer release and Investor Day notice | Aug. 10 and Sep. 24 | Candidate comparison: Q2 continuing-operations results, divestiture proceeds, and next-day event |
| Jabil Q3 FY26 issuer results and Q4/FY26 release notice | Jun. 17 and Sep. 9 | Candidate comparison: Q3 performance, FY26 guide and next-day report/strategic priorities |
| Finance-feed references for KMX, CNDT, JBL, and SPY | Sep. 29, approx. 12:45-12:55 p.m. EDT | Candidate and broad-market reference prices; provider fields are not execution or positioning data |
Research Quality Scorecard
| Criterion | Score | Reason |
|---|---|---|
| Market disagreement | 3 | Weak FY27 operating guide contrasts with a low 9.66x adjusted-EPS reference multiple, but current Q1 expectations are not verified |
| Evidence base | 3 | Issuer FY26 results and Q1 schedule are reliable, but the latest quarter and Q1 expectations are still unknown |
| Positioning and flows | 2 | Price/volume references exist, but short interest, borrow, options and current order-book evidence are missing |
| Catalyst path | 4 | Q1 release and Q&A are dated within one session with direct tests of volume, margin, cash and guidance |
| Payoff architecture | 1 | Base is flat, adverse reference stress +15.0%, reward/adverse 0:1, and gross expected short value -1.1% |
| Invalidation discipline | 4 | Guide retention, organic volume, adjusted margin, cash conversion and net leverage are monitorable |
| Differentiated insight | 4 | Separates the non-cash impairment from recurring weakness and recognizes that the reduced dividend and low guide multiple already change the short asymmetry |
| Client value | 5 | Prevents a known guide decline and next-day binary event from being mistaken for a proven 10/5 short |
| Total | 26/40 | Reject / no-trade screen; failed 10/5 economics override the score |
Bottom Line
Conagra enters the Sep. 30 Q1 release with a genuinely weaker FY27 guide, lower cash generation, and leverage near 4x. But the market has already cut the dividend, the stock has fallen about 13.1% from Sep. 1, and $14.005 is only 9.66x the issuer’s adjusted-EPS midpoint. The one-week reference map has no base decline, a +15.0% rebound stress, and negative expected gross short value before costs. Reject / no trade.
AI Illustration Prompt
A sober pre-earnings desk still life for a packaged-food company: a Conagra earnings folder marked “Q1 FY27, before open Sep. 30” rests beside four grocery-segment ledgers showing FY27 organic sales “-3% to -1%,” adjusted margin “10.0%-10.5%,” EPS “$1.40-$1.50,” and year-end leverage “~4.0x.” A calendar highlights the 9:30 a.m. ET Q&A. A small price card reads “$14.005 at 12:55 p.m. EDT Sep. 29; 9.66x guide midpoint,” while a pencil chart marks the observed $12.53 52-week low and Sep. 1 $16.11 close with a note “reference levels, not floor/cap.” Include small counters for FY26 free cash flow “$979M vs $1.3B” and annual dividend “$0.70.” Restrained editorial realism, cream paper, navy ink, muted grocery colors, no falling-arrow cliché or guaranteed thesis. Add a subtle readable “The Mispricing Desk” watermark.